colorectal cancer
Conditions
Interventions
None listed
Sponsors
Japanese Society for Cancer of the Colon and Rectum
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who were treated with regorafenib or TAS-102 between 26th May 2014 and 30th September 2015. 2) Histologically proven colorectal adenocarcinoma 3) Unresectable colorectal cancer 4) Refractory to fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and anti-EFGR antibody (limited KRAS or RAS wild type) 5) With measurable or evaluable lesion 6) Age <=20 years old 7) ECOG PS 0 to 2
Exclusion criteria
Exclusion criteria: 1) Prior therapy with regorafenib or TAS-102 2) Active infections 3) Symptomatic brain metastasis 4) Active double cancers 5) Serious complications 6) Uncontrolled thromboembolism 7) Comorbidity with systemic steroid therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, response rate, disease control rate, time to treatment failure, time to ECOG PS >=2, incidence of adverse events, detail of subsequent treatment, and comparison between patients with initial dose reduction and patients without it. | — |
Countries
Japan
Contacts
Public ContactToshikazu Moriwaki
University of Tsukuba Division of Gastroenterology
Outcome results
None listed